Sermonix announces five abstracts at 2023 SABCS

Sermonix Pharmaceuticals announced that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium, SABCS, which will be held Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio. Three posters delve into clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations studies. One assesses baseline genomic alterations and the activity of lasofoxifene, Sermonix’s investigational novel endocrine therapy, and Eli Lilly and Company’s (LLY) CDK4/6 inhibitor abemaciclib during the ELAINE-2 study. A second poster addresses pharmacokinetics of lasofoxifene as a monotherapy and in combination with abemaciclib. The third poster is a trial-in-progress update on ELAINE-3, which is studying the efficacy and safety of lasofoxifene in combination with abemaciclib in treating locally advanced or ER+/HER2- mBC with an ESR1 mutation. Sermonix licensed Lasofoxifene globally from Ligand Pharmaceuticals (LGND)